ProBioGen and the Berlin Institute of Health at Charité (BIH) announced at the groundbreaking ceremony for the Berlin Center for Gene and Cell Therapies (BC GCT) that they will collaborate on the development and production of clinical material for gene and cell therapies. In the course of the BC GCT, a 4,600 m² GMP-compliant production facility for advanced therapies is being built. ProBioGen will take over the expansion and operation of the plant in the BC GCT. The project, which was commissioned by the BIH, will be funded by the Federal Ministry of Research, Technology and Space (BMFTR) with 76.5 million euros over the next 10 years.

The production facility is part of a unique innovation hub for gene- and cell-based therapies. The public-private joint project BC GCT combines research, development and GMP-compliant production under one roof to significantly accelerate the development of novel medicines – from discovery to clinical application. In addition to the production facility, the center is home to a start-up incubator for gene and cell therapies, operated by the joint GmbH of Charité – Universitätsmedizin Berlin and Bayer AG. The aim of the center is to provide start-ups and clinical innovators with a powerful infrastructure, world-class expertise and comprehensive regulatory and business support – so that innovative therapies find their way to patients faster, safer and with a higher chance of success.

Gene and cell-based therapies (GCTs) are among the most innovative and promising areas of modern medicine. They address the genetic or epigenetic causes of diseases directly and thus open up new chances of recovery for patients with serious or previously incurable diseases. With the National Strategy for Gene and Cell-Based Therapies, which is coordinated by the BIH on behalf of the federal government, Germany is pursuing the goal of strengthening the entire value chain – from basic research and clinical development to broad patient access – and sustainably securing the country’s leading international position in this forward-looking field of therapy.

Read Also:

Dietmar Hopp Foundation supports gene therapy research in Heidelberg – MedLabPortal

Editor: X-Press Journalistenbüro GbR

Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.